Pimozide ventricular arrhythmias caused

VENLAFAXINE 1. ANTIARRHYTHMICS - amiodarone, disopyramide, procainamide, propafenone 2. ANTIBIOTICS — macrolides (especially azithromycin, clarithromycin, parenteral erythromycin, telithromycin), quinolones (especially moxifloxacin), quinupristin/ dalfopristin 3. ANTICANCER AND IMMUNOMODULATING DRUGS -arsenic trioxide 4. ANTIDEPRESSANTS-TCAs 5. ANTIEMETICS-dolasetron 6. ANTIFUNGALS-fluconazole, posaconazole, voriconazole 7. ANTIHISTAMINES-terfenadine, hydroxyzine, mizolastine 8. ANTIMALARIALS -artemetherwith lumefantrine, chloro-quine, hydroxychloroquine, mefloquine, quinine 9. ANTIPROTOZOALS -pentamidine isetionate 10. ANTIPSY-CHOTICS - atypicals, phenothiazines, pimozide 11. BETA-BLOCKERS -sotalol 12. BRONCHODILATORS-parenteral bronchodilators 13. CNS STIMULANTS - atomoxetine Risk of ventricular arrhythmias, particularly torsades de pointes Additive effect these drugs cause prolongation of the Q-T interval Avoid co-administration... 

Because pimozide has anticholinergic properties, it is contraindicated in patients with arrhythmias because the drug may cause ventricular arrhythmias or aggravate existing arrhythmias in patients with congenital Q-T syndrome because it may cause conduction defects and sudden death and in comatose states and CNS depression because of the risk of addictive effects. 

Telithromycin may cause clinically significant QTc prolongation and increased risk of ventricular arrhythmia in predisposed patients. It should not be used in patients with prolonged QT syndrome, uncorrected hypokalemia or hypomagnesemia, profound bradycardia, or in patients receiving certain antiarrhythmics (e.g., quinidine, procainamide, amiodarone) or other agents that prolong QTc (e.g., cisapride, pimozide). 

Absolute aprepitant is contraindicated in patients who are hypersensitive to any component of the product. Aprepitant is a weak-to-moderate (dose-dependent) cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitor. Aprepitant should not be used concurrently with pimozide, terfenadine, astemizole, or cisapride. Dose-dependent inhibition of CYP3A4 by aprepitant could result in elevated plasma concentrations of these drugs, potentially causing serious or life-threatening ventricular arrhythmias. 

---